{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:34:03Z","timestamp":1784921643633,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,5,20]],"date-time":"2016-05-20T00:00:00Z","timestamp":1463702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Seventh Framework Programme (FP7)","award":["294582"],"award-info":[{"award-number":["294582"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft (DE)","doi-asserted-by":"publisher","award":["SFB 824, Project Z1"],"award-info":[{"award-number":["SFB 824, Project Z1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Seventh Framework Programme (FP7)","award":["256984"],"award-info":[{"award-number":["256984"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s00259-016-3424-3","type":"journal-article","created":{"date-parts":[[2016,5,20]],"date-time":"2016-05-20T10:20:47Z","timestamp":1463739647000},"page":"1962-1970","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC\u2014a PSMA specific probe for PET imaging of prostate cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Christian H.","family":"Pfob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Philipp","family":"Graner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"K\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Schachoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Blechert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Scheidhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schwaiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,20]]},"reference":[{"issue":"6","key":"3424_CR1","first-page":"855","volume":"54","author":"RC Walker","year":"2013","unstructured":"Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M. Measured human dosimetry of 68Ga-DOTATATE. J Nucl Med Off Publ Soc Nucl Med. 2013;54(6):855\u201360.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"3424_CR2","doi-asserted-by":"crossref","unstructured":"Breeman WAP, Chan HS, de Zanger RMS, Konijnenberg MK, Blois E de. Overview of Development and Formulation of 177Lu-DOTA-TATE for PRRT. Curr Radiopharm. 2015","DOI":"10.2174\/1874471008666150313111131"},{"issue":"2","key":"3424_CR3","first-page":"500","volume":"35","author":"MS Hofman","year":"2015","unstructured":"Hofman MS, Lau WFE, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiogr Rev Publ Radiol Soc North Am Inc. 2015;35(2):500\u201316.","journal-title":"Radiogr Rev Publ Radiol Soc North Am Inc"},{"issue":"1","key":"3424_CR4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/2191-219X-2-28","volume":"2","author":"J Notni","year":"2012","unstructured":"Notni J, Pohle K, Wester H-J. Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET. EJNMMI Res. 2012;2(1):28.","journal-title":"EJNMMI Res"},{"issue":"1","key":"3424_CR5","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res Off J Am Assoc Cancer Res. 1997;3(1):81\u20135.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"4","key":"3424_CR6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/ncpuro0452","volume":"3","author":"NH Bander","year":"2006","unstructured":"Bander NH. Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol. 2006;3(4):216\u201325.","journal-title":"Nat Clin Pract Urol"},{"issue":"4","key":"3424_CR7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder M, Sch\u00e4fer M, Bauder-W\u00fcst U, Hull W-E, W\u00e4ngler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23(4):688\u201397.","journal-title":"Bioconjug Chem"},{"issue":"2","key":"3424_CR8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197\u2013209.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"3424_CR9","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00259-013-2660-z","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET\/CT and PET\/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41(5):887\u201397.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"3424_CR10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3424_CR11","doi-asserted-by":"crossref","unstructured":"Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA-ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med Off Publ Soc Nucl Med. 2015","DOI":"10.2967\/jnumed.115.154153"},{"issue":"7","key":"3424_CR12","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00259-014-2713-y","volume":"41","author":"CM Zechmann","year":"2014","unstructured":"Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a (124)I\/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41(7):1280\u201392.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3424_CR13","doi-asserted-by":"crossref","unstructured":"Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The novel theranostic PSMA-ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry and first evaluation of tumor lesions. J Nucl Med Off Publ Soc Nucl Med. 2015","DOI":"10.2967\/jnumed.115.161299"},{"issue":"6","key":"3424_CR14","first-page":"855","volume":"56","author":"K Herrmann","year":"2015","unstructured":"Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester H-J, Czernin J, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med Off Publ Soc Nucl Med. 2015;56(6):855\u201361.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"3424_CR15","unstructured":"Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol [Internet]. 2016 Feb 23 [cited 2016 Mar 10];advance online publication. Available from: http:\/\/www.nature.com\/nrurol\/journal\/vaop\/ncurrent\/abs\/nrurol.2016.26.html"},{"issue":"1","key":"3424_CR16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.nucmedbio.2013.09.002","volume":"41","author":"R Martin","year":"2014","unstructured":"Martin R, J\u00fcttler S, M\u00fcller M, Wester H-J. Cationic eluate pretreatment for automated synthesis of [68Ga]CPCR4.2. Nucl Med Biol. 2014;41(1):84\u20139.","journal-title":"Nucl Med Biol"},{"key":"3424_CR17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2191-219X-2-23","volume":"2","author":"M Schafer","year":"2012","unstructured":"Schafer M, Bauder-Wust U, Leotta K, Zoller F, Mier W, Haberkorn U, et al. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res. 2012;2:23.","journal-title":"EJNMMI Res"},{"issue":"12","key":"3424_CR18","first-page":"1914","volume":"52","author":"G Delso","year":"2011","unstructured":"Delso G, F\u00fcrst S, Jakoby B, Ladebeck R, Ganter C, Nekolla SG, et al. Performance measurements of the Siemens mMR integrated whole-body PET\/MR scanner. J Nucl Med Off Publ Soc Nucl Med. 2011;52(12):1914\u201322.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"4","key":"3424_CR19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.zemedi.2012.08.003","volume":"22","author":"A Martinez-M\u00f6ller","year":"2012","unstructured":"Martinez-M\u00f6ller A, Nekolla SG. Attenuation correction for PET\/MR: problems, novel approaches and practical solutions. Z F\u00fcr Med Phys. 2012;22(4):299\u2013310.","journal-title":"Z F\u00fcr Med Phys"},{"issue":"9","key":"3424_CR20","first-page":"1415","volume":"53","author":"A Martinez-M\u00f6ller","year":"2012","unstructured":"Martinez-M\u00f6ller A, Eiber M, Nekolla SG, Souvatzoglou M, Drzezga A, Ziegler S, et al. Workflow and scan protocol considerations for integrated whole-body PET\/MRI in oncology. J Nucl Med Off Publ Soc Nucl Med. 2012;53(9):1415\u201326.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"Suppl 1","key":"3424_CR21","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1007\/s00259-013-2445-4","volume":"40","author":"M Souvatzoglou","year":"2013","unstructured":"Souvatzoglou M, Eiber M, Martinez-Moeller A, F\u00fcrst S, Holzapfel K, Maurer T, et al. PET\/MR in prostate cancer: technical aspects and potential diagnostic value. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 1:S79\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"3424_CR22","first-page":"520","volume":"50","author":"A Martinez-M\u00f6ller","year":"2009","unstructured":"Martinez-M\u00f6ller A, Souvatzoglou M, Delso G, Bundschuh RA, Chefd\u2019hotel C, Ziegler SI, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET\/MRI: evaluation with PET\/CT data. J Nucl Med Off Publ Soc Nucl Med. 2009;50(4):520\u20136.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"8","key":"3424_CR23","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2967\/jnumed.115.156711","volume":"56","author":"AT Soderlund","year":"2015","unstructured":"Soderlund AT, Chaal J, Tjio G, Totman JJ, Conti M, Townsend DW. Beyond 18F-FDG: characterization of PET\/CT and PET\/MR scanners for a comprehensive Set of positron emitters of growing application\u201418F, 11C, 89Zr, 124I, 68Ga, and 90Y. J Nucl Med. 2015;56(8):1285\u201391.","journal-title":"J Nucl Med"},{"issue":"1","key":"3424_CR24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/HP.0b013e318228e5b4","volume":"102","author":"JA Siegel","year":"2012","unstructured":"Siegel JA, Stabin MG. Radar commentary: use of linear no-threshold hypothesis in radiation protection regulation in the United States. Health Phys. 2012;102(1):90\u20139.","journal-title":"Health Phys"},{"issue":"11","key":"3424_CR25","first-page":"1807","volume":"53","author":"MG Stabin","year":"2012","unstructured":"Stabin MG, Xu XG, Emmons MA, Segars WP, Shi C, Fernald MJ. RADAR reference adult, pediatric, and pregnant female phantom series for internal and external dosimetry. J Nucl Med Off Publ Soc Nucl Med. 2012;53(11):1807\u201313.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"7","key":"3424_CR26","first-page":"1156","volume":"52","author":"MG Stabin","year":"2011","unstructured":"Stabin MG, Sharkey RM, Siegel JA. RADAR commentary: evolution and current status of dosimetry in nuclear medicine. J Nucl Med Off Publ Soc Nucl Med. 2011;52(7):1156\u201361.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"5","key":"3424_CR27","first-page":"853","volume":"49","author":"MG Stabin","year":"2008","unstructured":"Stabin MG. Uncertainties in internal dose calculations for radiopharmaceuticals. J Nucl Med Off Publ Soc Nucl Med. 2008;49(5):853\u201360.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"3424_CR28","unstructured":"Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. Soc Nucl Med. 1988. 152."},{"issue":"2","key":"3424_CR29","first-page":"37S","volume":"40","author":"JA Siegel","year":"1999","unstructured":"Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical Biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med Off Publ Soc Nucl Med. 1999;40(2):37S\u201361S.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"1","key":"3424_CR30","first-page":"81","volume":"89","author":"I Janssen","year":"2000","unstructured":"Janssen I, Heymsfield SB, Wang ZM, Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18\u201388 yr. J Appl Physiol Bethesda Md 1985. 2000;89(1):81\u20138.","journal-title":"J Appl Physiol Bethesda Md 1985"},{"issue":"4","key":"3424_CR31","first-page":"689","volume":"34","author":"G Sgouros","year":"1993","unstructured":"Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med Off Publ Soc Nucl Med. 1993;34(4):689\u201394.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"12","key":"3424_CR32","first-page":"2102","volume":"40","author":"S Shen","year":"1999","unstructured":"Shen S, DeNardo GL, Sgouros G, O\u2019Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med Off Publ Soc Nucl Med. 1999;40(12):2102\u20136.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"4 Suppl","key":"3424_CR33","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/cncr.24797","volume":"116","author":"L Ferrer","year":"2010","unstructured":"Ferrer L, Kraeber-Bod\u00e9r\u00e9 F, Bodet-Milin C, Rousseau C, Le Gouill S, Wegener WA, et al. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer. 2010;116(4 Suppl):1093\u2013100.","journal-title":"Cancer"},{"issue":"6","key":"3424_CR34","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med Off Publ Soc Nucl Med. 2005;46(6):1023\u20137.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"4","key":"3424_CR35","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","volume":"52","author":"SD Sweat","year":"1998","unstructured":"Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637\u201340.","journal-title":"Urology"},{"issue":"2","key":"3424_CR36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12253-008-9104-2","volume":"15","author":"S Mannweiler","year":"2009","unstructured":"Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15(2):167\u201372.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"3424_CR37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4103\/0973-1482.131461","volume":"10","author":"T Maria","year":"2014","unstructured":"Maria T, Panagiotis A, Marina C, Eleni K, Ioanna V, Georgia M, et al. How prostate-specific membrane antigen level may be correlated with stemness in prostate cancer stem cell-like cell populations? J Cancer Res Ther. 2014;10(1):133\u201341.","journal-title":"J Cancer Res Ther"},{"issue":"supplement 1","key":"3424_CR38","first-page":"1083","volume":"55","author":"M Weineisen","year":"2014","unstructured":"Weineisen M, Schottelius M, Simecek J, Eiber M, Schwaiger M, Wester H. Development and first in human evaluation of PSMA I&T - A ligand for diagnostic imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2014;55(supplement 1):1083\u20133.","journal-title":"J Nucl Med"},{"issue":"6","key":"3424_CR39","first-page":"914","volume":"56","author":"M Bene\u0161ov\u00e1","year":"2015","unstructured":"Bene\u0161ov\u00e1 M, Sch\u00e4fer M, Bauder-W\u00fcst U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med Off Publ Soc Nucl Med. 2015;56(6):914\u201320.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"4","key":"3424_CR40","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","volume":"17","author":"Z Szabo","year":"2015","unstructured":"Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol MIB Off Publ Acad Mol Imaging. 2015;17(4):565\u201374.","journal-title":"Mol Imaging Biol MIB Off Publ Acad Mol Imaging"},{"issue":"1","key":"3424_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12149-014-0898-6","volume":"29","author":"RA Werner","year":"2015","unstructured":"Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, Herrmann K. 68Gallium- and 90Yttrium-\/177Lutetium: \u201ctheranostic twins\u201d for diagnosis and treatment of NETs. Ann Nucl Med. 2015;29(1):1\u20137.","journal-title":"Ann Nucl Med"},{"issue":"1\u20132","key":"3424_CR42","first-page":"1","volume":"38","author":"ICRP","year":"2008","unstructured":"ICRP. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP publication 53. ICRP publication 106. Approved by the commission in october 2007. Ann ICRP. 2008;38(1\u20132):1\u2013197.","journal-title":"Ann ICRP"},{"issue":"6","key":"3424_CR43","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2967\/jnumed.111.099408","volume":"53","author":"A Giussani","year":"2012","unstructured":"Giussani A, Janzen T, Uusij\u00e4rvi-Lizana H, Tavola F, Zankl M, Sydoff M, et al. A compartmental model for biokinetics and dosimetry of 18F-choline in prostate cancer patients. J Nucl Med. 2012;53(6):985\u201393.","journal-title":"J Nucl Med"},{"issue":"5","key":"3424_CR44","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s00259-009-1346-z","volume":"37","author":"T Tolvanen","year":"2010","unstructured":"Tolvanen T, Yli-Kerttula T, Ujula T, Autio A, Lehikoinen P, Minn H, et al. Biodistribution and radiation dosimetry of [(11)C]choline: a comparison between rat and human data. Eur J Nucl Med Mol Imaging. 2010;37(5):874\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"3424_CR45","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00259-013-2502-z","volume":"40","author":"K Smolarz","year":"2013","unstructured":"Smolarz K, Krause BJ, Graner FP, Wagner FM, Wester H-J, Sell T, et al. Biodistribution and radiation dosimetry in healthy volunteers of a novel tumour-specific probe for PET\/CT imaging: BAY 85\u20138050. Eur J Nucl Med Mol Imaging. 2013;40(12):1861\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"3424_CR46","first-page":"191","volume":"55","author":"M Eiber","year":"2014","unstructured":"Eiber M, Takei T, Souvatzoglou M, Mayerhoefer ME, F\u00fcrst S, Gaertner FC, et al. Performance of whole-body integrated 18F-FDG PET\/MR in comparison to PET\/CT for evaluation of malignant bone lesions. J Nucl Med Off Publ Soc Nucl Med. 2014;55(2):191\u20137.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"Suppl 1","key":"3424_CR47","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1007\/s00259-008-1007-7","volume":"36","author":"M Hofmann","year":"2009","unstructured":"Hofmann M, Pichler B, Sch\u00f6lkopf B, Beyer T. Towards quantitative PET\/MRI: a review of MR-based attenuation correction techniques. Eur J Nucl Med Mol Imaging. 2009;36 Suppl 1:S93\u2013104.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"3424_CR48","first-page":"923","volume":"55","author":"S Hitz","year":"2014","unstructured":"Hitz S, Habekost C, F\u00fcrst S, Delso G, F\u00f6rster S, Ziegler S, et al. Systematic comparison of the performance of integrated whole-body PET\/MR imaging to conventional PET\/CT for 18F-FDG brain imaging in patients examined for suspected dementia. J Nucl Med Off Publ Soc Nucl Med. 2014;55(6):923\u201331.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"5","key":"3424_CR49","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/RLI.0b013e31828234d0","volume":"48","author":"FC Gaertner","year":"2013","unstructured":"Gaertner FC, Beer AJ, Souvatzoglou M, Eiber M, F\u00fcrst S, Ziegler SI, et al. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography\/magnetic resonance in comparison with positron emission tomography\/computed tomography in patients with neuroendocrine tumors. Invest Radiol. 2013;48(5):263\u201372.","journal-title":"Invest Radiol"},{"issue":"10","key":"3424_CR50","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s00259-013-2467-y","volume":"40","author":"M Souvatzoglou","year":"2013","unstructured":"Souvatzoglou M, Eiber M, Takei T, F\u00fcrst S, Maurer T, Gaertner F, et al. Comparison of integrated whole-body [11C]choline PET\/MR with PET\/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(10):1486\u201399.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3424_CR51","doi-asserted-by":"crossref","unstructured":"Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic Efficacy of (68) Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging in Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2015","DOI":"10.1016\/j.juro.2015.12.025"},{"issue":"10","key":"3424_CR52","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1007\/s00259-015-3065-y","volume":"42","author":"FA Verburg","year":"2015","unstructured":"Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET\/CT. Eur J Nucl Med Mol Imaging. 2015;42(10):1622\u20133.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"3424_CR53","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00261-014-0301-z","volume":"40","author":"M Eiber","year":"2015","unstructured":"Eiber M, Nekolla SG, Maurer T, Weirich G, Wester H-J, Schwaiger M. (68)Ga-PSMA PET\/MR with multimodality image analysis for primary prostate cancer. Abdom Imaging. 2015;40(6):1769\u201371.","journal-title":"Abdom Imaging"},{"issue":"3","key":"3424_CR54","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.eururo.2015.04.034","volume":"68","author":"T Maurer","year":"2015","unstructured":"Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015;68(3):530\u20134.","journal-title":"Eur Urol"},{"issue":"7","key":"3424_CR55","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00120-015-3868-2","volume":"54","author":"T Maurer","year":"2015","unstructured":"Maurer T, K\u00fcbler H, Gschwend JE, Eiber M. Positron-emission tomography in urooncology. Urol Ausg. 2015;54(7):983\u201391.","journal-title":"Urol Ausg"},{"issue":"12","key":"3424_CR56","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1007\/s00259-012-2210-0","volume":"39","author":"A Boubaker","year":"2012","unstructured":"Boubaker A, Prior JO, Willi J-P, Champendal M, Kosinski M, Bischof Delaloye A, et al. Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide. Eur J Nucl Med Mol Imaging. 2012;39(12):1868\u201375.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3424_CR57","doi-asserted-by":"crossref","unstructured":"The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37(2\u20134):1\u2013332.","DOI":"10.1016\/j.icrp.2008.07.001"},{"issue":"3","key":"3424_CR58","first-page":"410","volume":"56","author":"K Herrmann","year":"2015","unstructured":"Herrmann K, Lapa C, Wester H-J, Schottelius M, Schiepers C, Eberlein U, et al. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor. J Nucl Med Off Publ Soc Nucl Med. 2015;56(3):410\u20136.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3424-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-016-3424-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3424-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T08:37:19Z","timestamp":1600591039000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-016-3424-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,20]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["3424"],"URL":"https:\/\/doi.org\/10.1007\/s00259-016-3424-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,20]]}}}